Immunitybio Inc

IBRX remains in a Stage 2 consolidation above its rising 200DMA after the mid-Feb parabolic spike and collapse. Short-term EMAs (9/20/50) are flat and price sits slightly below the cluster, with neutral RSI and Options Score signaling no clear timing edge. Medium-term bias stays bullish in this range-bound structure, but execution should await support near the lower range or a decisive reclaim of the EMA cluster.

• ↑Q2 2026 net revenues $50.7 M, up 92% YoY.
• ↑ANKTIVA revenues projected to hit $210 M (+85% YoY) in 2026.
• ↓Negative profitability factors suggest unsustainable margin structure.